Bleichroeder’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-3,893,730
Closed -$16.4M – 90
2023
Q1
$16.4M Hold
3,893,730
– – 3.49% 8
2022
Q4
$23.4M Sell
3,893,730
-50,000
-1% -$273K 5.09% 5
2022
Q3
$23M Sell
3,943,730
-5,000
-0.1% -$31.2K 4.79% 6
2022
Q2
$23.6M Buy
3,948,730
+89,023
+2% +$456K 4.87% 6
2022
Q1
$18M Buy
3,859,707
+3,609,707
+1,444% +$10.8M 3.2% 7
2021
Q4
$620K Buy
+250,000
New +$612K 0.1% 59

Other funds holding CTIC

Bleichroeder's CTIC Position: Q2 2023 in Review

Bleichroeder sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3,893,730 shares — an estimated $16.4M sold.

Bleichroeder first reported a position in CTIC in Q4 2021 and held it in 6 quarters. The position peaked at $23.6M in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • Bleichroeder reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bleichroeder sold 3,893,730 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $16.4M.
  • Bleichroeder first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 6 quarters.
  • Bleichroeder's CTI BioPharma Corp. (DE) Common Stock position peaked at $23.6M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Bleichroeder's 13F filing for Q2 2023, filed 14 Aug 2023.